The protein sequencing market is estimated to be valued at US$ 1.9 Bn in 2022 and is expected to exhibit a CAGR of 11.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

 

The protein sequencing market consists of technologies and consumables used for determining the amino acid sequence of proteins. Protein sequencing finds widespread application in proteomics research, biotherapeutics development and clinical diagnostics. Advances in mass spectrometry platforms have accelerated protein sequencing workflows, enabling identification and characterization of thousands of proteins in a single experiment.

 

Rising government funding for proteomics and biomarker research worldwide represents a key factor driving the protein sequencing market. Many public and private funding agencies are supporting the development of advanced tools and technologies for large-scale protein analysis. For instance, the National Institutes of Health allocated over US$ 650 million for the Human Proteome Project in 2022. In addition, growing demand for personalized medicines has boosted pharmaceutical R&D investment in target identification and validation using protein sequencing methods. Technologies such as mass spectrometry enable evaluation of protein expression changes associated with disease pathogenesis, fuelling their incorporation in preclinical drug discovery.

 

Protein sequencing market is witnessing increasing adoption of next-generation sequencing technology. NGS provides high-throughput capabilities for sequencing proteins at a much faster rate and lower cost as compared to conventional Sanger sequencing. Sanger sequencing faces limitations such as requirement of prior knowledge of sequence and high costs. The introduction of NGS platforms such as Illumina sequencing and Ion Torrent has significantly increased the sequencing output and reduced the time and expenses involved in protein sequencing. Additionally, growing applications of protein sequencing in areas such as proteomics, drug discovery, immunology and cancer research is driving the adoption of advanced protein sequencing methods.

 

Strengths: Next generation sequencing technology provides high-throughput capabilities and lowers the cost of protein sequencing.

Weaknesses: Requirement of large capital investment and advanced data analytics skills for NGS-based protein sequencing.

Opportunities: Growing applications in proteomics, drug discovery, cancer research and immunology are expanding the scope of protein sequencing.

Threats: High risks of misinterpretation of large genomic and proteomic data generated through NGS without comprehensive bioinformatics analysis.

 

Global Protein Sequencing Market Size is expected to witness high growth, exhibiting CAGR of 11.2% over the forecast period, due to increasing demand for advanced protein analysis in proteomics and drug discovery research.

 

Regional analysis: North America dominates the global protein sequencing market led by presence of major players and growing proteomics research in the region. The Asia Pacific region also offers lucrative opportunities for market expansion over the coming years supported by increasing investments in healthcare sector of developing countries like India and China.

 

Key players: Key players operating in the protein sequencing market are Agilent Technologies, Thermo Fisher Scientific, SGS S.A., Shimadzu Corp, Waters Corp., Bio-Rad Laboratories, Bruker Corporation, Charles River Laboratories, Selvita, Rapid Novor Inc. These companies are focusing on launching innovative sequencing instruments and services to expand their market share.

The protein sequencing market is estimated to be valued at US$ 1.9 Bn in 2022 and is expected to exhibit a CAGR of 11.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

 

The protein sequencing market consists of technologies and consumables used for determining the amino acid sequence of proteins. Protein sequencing finds widespread application in proteomics research, biotherapeutics development and clinical diagnostics. Advances in mass spectrometry platforms have accelerated protein sequencing workflows, enabling identification and characterization of thousands of proteins in a single experiment.

 

Rising government funding for proteomics and biomarker research worldwide represents a key factor driving the protein sequencing market. Many public and private funding agencies are supporting the development of advanced tools and technologies for large-scale protein analysis. For instance, the National Institutes of Health allocated over US$ 650 million for the Human Proteome Project in 2022. In addition, growing demand for personalized medicines has boosted pharmaceutical R&D investment in target identification and validation using protein sequencing methods. Technologies such as mass spectrometry enable evaluation of protein expression changes associated with disease pathogenesis, fuelling their incorporation in preclinical drug discovery.

 

Protein sequencing market is witnessing increasing adoption of next-generation sequencing technology. NGS provides high-throughput capabilities for sequencing proteins at a much faster rate and lower cost as compared to conventional Sanger sequencing. Sanger sequencing faces limitations such as requirement of prior knowledge of sequence and high costs. The introduction of NGS platforms such as Illumina sequencing and Ion Torrent has significantly increased the sequencing output and reduced the time and expenses involved in protein sequencing. Additionally, growing applications of protein sequencing in areas such as proteomics, drug discovery, immunology and cancer research is driving the adoption of advanced protein sequencing methods.

 

Strengths: Next generation sequencing technology provides high-throughput capabilities and lowers the cost of protein sequencing.

Weaknesses: Requirement of large capital investment and advanced data analytics skills for NGS-based protein sequencing.

Opportunities: Growing applications in proteomics, drug discovery, cancer research and immunology are expanding the scope of protein sequencing.

Threats: High risks of misinterpretation of large genomic and proteomic data generated through NGS without comprehensive bioinformatics analysis.

 

Global Protein Sequencing Market Size is expected to witness high growth, exhibiting CAGR of 11.2% over the forecast period, due to increasing demand for advanced protein analysis in proteomics and drug discovery research.

 

Regional analysis: North America dominates the global protein sequencing market led by presence of major players and growing proteomics research in the region. The Asia Pacific region also offers lucrative opportunities for market expansion over the coming years supported by increasing investments in healthcare sector of developing countries like India and China.

 

Key players: Key players operating in the protein sequencing market are Agilent Technologies, Thermo Fisher Scientific, SGS S.A., Shimadzu Corp, Waters Corp., Bio-Rad Laboratories, Bruker Corporation, Charles River Laboratories, Selvita, Rapid Novor Inc. These companies are focusing on launching innovative sequencing instruments and services to expand their market share.